

## Drug Monograph

Drug Name: **Oxbryta® (voxelotor) tablet for suspension**  
 Drug Class: **Hematological Agents: Sickle Cell Disease Agents**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Oxbryta is now available as a 300 mg tablet for suspension.

**Manufacturer:** Distributed by: Global Blood Therapeutics, Inc., South San Francisco, CA 94080.

**Indications:** Oxbryta is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

**Costs:** \$10,417 per 60 or 90 tablets Wholesale Acquisition Cost

**Summary of Findings:** The MO Healthnet Division recommends adding this drug to the current Sickle Cell Disease clinical edit.

**Status Recommendation:** ☒ Clinical Edit ☐ PA Required  
☐ Open Access ☐ PDL

**Type of PA Criteria:** ☒ Appropriate Indications ☐ Non-Preferred  
☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD  
 Date: January 6, 2022